We have synthesized and characterized doxorubicin (DOX)-loaded galactosylated gelatin nanovectors using in vitro and in vivo for targeting liver cells including hepatocarcinoma cells. Galactosylated and nongalactosylated gelatin nanovectors (GL-GN-DOX and GN-DOX) were spherical in shape and had mean sizes of about 95.1 and 88.3 nm, respectively. In-vitro release of DOX from nanovectors followed first-order kinetics and was pH dependent. Galactosylated formulation released 95.2% of DOX compared with 86.6% by nongalactosylated formulation at pH 5.8. However, the release rate was suppressed at pH 7.4. Further, we showed that GL-GN-DOX had greater growth inhibitory effect on HepG2 in terms of low inhibitory concentration (IC 50 ; 0.35 lg/ml) compared with GN-DOX (0.75 lg/ml) and induced caspase-3-mediated apoptosis in HepG2 cells. This might be due to efficient internalization of galactosylated nanovectors by HepG2 cells compared with unmodified formulation. Pharmacokinetic and biodistribution analyses show that galactosylated formulation deposits 24.5 lg/g of DOX in targeted tissue (liver) in comparison with heart (0.3 lg/g) at a single dose of 10 mg/kg. These results suggest that DOX-loaded galactosylated gelatin nanovectors warrant future in-depth antitumor study to scale-up technology and may be used for the management of hepatocarcinoma.
Introduction
Liver cancer is the fifth most common malignancy in men and the eighth in women worldwide and is estimated at 564 000 new cases per year, including 398 000 in men and 166 000 in women [1] . Liver tumor can be classified as hepatocellular carcinoma (HCC) and cholangiocarcinoma. However, HCC is 10 times more common and is responsible for 90% of primary malignant liver tumors in adults [2] . The currently available therapies for the treatment of HCC are (a) liver transplantation and hepatic resection, (b) embolization and chemoembolization, (c) ethanol injection, radio-frequency ablation, cryoablation, and ultrasound ablation, (d) radiation therapy, and (e) systemic therapy, which includes chemotherapeutic drugs, genes, and immune therapies [3] . Hepatic resection is limited in HCC patients because of high rates of reoccurrence and metastasis after surgery. Moreover, conventional chemotherapy is also associated with toxicity to normal tissues. Therefore, it is of considerable importance to search actively for more targetable chemotherapeutic drugs to improve the quality of life and survival rate of HCC patients. Among these, the rapid development of nanoscale-based targeted drug delivery systems holds tremendous promise for the treatment of HCC [4, 5] . Polymeric nanovectors have recently gained extensive attention because of their potential applica-tions in pharmaceutical science as a tool in drug delivery [4] [5] [6] . However, these nanovectors need active transport mechanisms to gain access in overexpressed tumor cell receptors. Therefore, nanomedicines can be targeted to the tumor network either through ligandinstructed nanocarriers and/or through enhanced permeability and retention effect [5, 7] . To achieve this goal, carbohydrate-based ligands commonly decorate over the surface of nanovectors for targeting hepatocarcinoma cells [8] .
Asialoglycoproteins (ASGPs) are the abundant heterooligomer endocytic receptors that are expressed on the sinusoidal surface of hepatocytes [4] . These lectins present on liver cells and bind ASGPs (glycoproteins from which sialic acid has been removed to expose galactose) to remove them from circulation. Thus, galactosylated nanovectors are used to enhance the intracellular concentration of chemotherapeutic drugs in liver cells including hepatocarcinoma cells [9, 10] . Lactobionic acid (4-O-b-galactopyranosyl-D-gluconic acid) yields gluconic acid and galactose on oxidation of lactose and acts as a template for the fabrication of galactosylated nanocarriers [11] . We reported that polymeric nanovesicles and microvesicles are the promising drug delivery systems for intracellular delivery of proteins and drugs [12] [13] [14] [15] [16] [17] [18] [19] .
Gelatin, a protein polymer, has already been approved by the US Food and Drug Administration for human consumption [5] . It is biodegradable, nontoxic, and nonimmunogenic in nature, and these unique properties greatly enhance its utility in nanotechnology to scale-up drug delivery systems [15, 18] . Therefore, we are actively engaged in the design and development of gelatin-based nanovectors for delivery of cytotoxic agents in human cancer cells [18] . Doxorubicin (DOX), a well-known clinically active cytotoxic agent, possesses strong antitumor activity against various solid tumors including HCC ( Fig. 1 ) [20] . However, the therapeutic potential of DOX is restricted because of low bioavailability and toxic side effects such as cardiotoxicity, myelosuppression, and leucopenia [21] . Moreover, the development of multidrug resistance with overexpression of permeability (P)glycoprotein (or CD 243) in tumor cells also leads to a marked decrease in drug sensitivity and efficacy [22] . Meng et al. [23] report that drug delivery nanocarriers have the potential to overcome these drawbacks of DOX.
Therefore, to achieve our aim, we have synthesized galactosylated gelatin nanovectors for intracellular delivery of DOX (GL-GN-DOX) to liver cells including hepatocarcinoma (HepG2) cells. Further, we conducted in-vitro and in-vivo studies for the characterization of these nanovectors using various spectroscopic techniques.
Materials and methods
Materials DOX [(8S,10S)-10-(4-amino-5-hydroxy-6-methyl-tetrahydro-2H-pyran-2-yl-oxy) 6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12 dione] and 2,4,6-trinitrobenzene sulfonic acid (TNBS) were obtained as gift samples. Lactobionic acid (4-O-b-Dgalactopyranosyl-D-gluconic acid), sodium bis(2-ethylhexyl sulfosuccinate) (AOT), and gelatin (type B; bloom strength B225 with an isoelectric point of 4.7-5.2 and average molecular weight of 40 000-50 000 Da) were purchased from Sigma Aldrich (Carlsbad, California, USA). 1-Ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide hydrochloride salt (EDAC.HCl) and N-hydroxysuccinimide were procured from Spectrochem (Mumbai, India). Glutaraldehyde (25% aqueous solution) was purchased from Loba Chemie (Mumbai, India). All other chemicals used were of analytical standard.
Cells and reagents
The human hepatocarcinoma cell line HepG2 was maintained in a 95% CO 2 atmosphere at 371C using Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal calf serum. All experiments were conducted with asynchronous populations in the exponential growth phase (24 h after plating).
Preparation and characterization of doxorubicin-loaded galactosylated gelatin nanovectors Synthesis and characterization of galactosylated gelatin
Lactobionic acid was conjugated to gelatin by EDAC chemistry [24] . Briefly, lactobionic acid (128 mg) was dissolved in 10 ml of distilled water (solution A) and EDAC/N-hydroxysuccinimide (four-fold molar excess) was separately dissolved in 10 ml of distilled water (solution B). Subsequently, solution B was added dropwise to solution A and the reaction mixture was vortex-mixed and incubated overnight at 41C. Gelatin (100 mg) was dissolved in 10 ml of distilled water (pH 5.3) and the activated lactobionic acid solution was added dropwise to the aqueous gelatin solution. The reaction mixture was vortexed and incubated overnight at 41C. The lactobionic acid-gelatin conjugate was then dialyzed (Sigma; 12 kDa) to remove the unreacted components against distilled water and lyophilized (Daihan Lab Tech, Hyderabad, India) and characterized using a differential scanning calorimeter (DSC 7; Perkin-Elmer, Thermal analyzer, Waltham, Massachusetts, USA). Argon was used as a carrier gas at a flow rate of 35 ml/min and scanning was carried out at a heating rate of 101C/min. The sample size was 7.5 mg, and curves were recorded at a temperature range of 50-3001C.
Measurement of free amine groups
The free amine groups in the lactobionic acid-gelatin conjugate were determined by the TNBS assay [25] . Briefly, 10 mg of gelatin or lactobionic acid-conjugated gelatin was mixed with 1 ml of 4% sodium bicarbonate (pH 8.5) and 1 ml of 0.1% TNBS. The mixture was kept in an incubator for 4 h at 401C in the dark with mild shaking. Subsequently, 3 ml of 6N HCl was added to the reaction mixture to hydrolyze any insoluble materials and heated at 701C for 1 h. The hydrolysate was diluted with distilled water (5 ml) and extracted with diethyl ether. A volume of 5 ml of the aqueous phase was removed from each sample and heated for 15 min, cooled to room temperature, and diluted with 15 ml of distilled water. Absorbance was measured at 340 nm in a UV-visible spectrophotometer (Shimadzu, Kyoto, Japan) against a blank. We have carried out the experiment in triplicate.
Preparation of gelatin and galactosylated gelatin nanovectors
Gelatin and galactosylated gelatin nanovectors bearing doxorubicin (GN-DOX and GL-GN-DOX) were prepared by the nanoemulsion method [15, 26] . Briefly, 800 ml of 0.05% w/v aqueous gelatin or lactobionic acidconjugated gelatin solution containing 20 mg of DOX was added to 50 ml of 0.03 mol/l AOT in n-hexane solution. About 10 ml of the crosslinking agent (glutaraldehyde; 25% w/v) was then added to provide rigidity to protein nanovectors. Subsequently, n-hexane was removed by evaporating in a rotary flash evaporator (Thermotech, Tamil Nadu, India), and the remaining dry mass was recovered by precipitation in an excess of acetonemethanol mixture (9 : 1). The precipitate was washed three times with acetone-methanol mixture to remove excess AOT. Finally, drug-loaded nanovectors were purified by dialysis (Sigma; 12 kDa) against distilled water at 41C and lyophilized (Daihan Lab Tech).
Determination of particle size and zeta potential
We used a particle size analyzer (Malvern Instruments, Malvern, UK) for determination of nanovector size and surface charge. Briefly, 100 ml of the nanovector suspension was added to 5 ml of phosphate buffer saline (pH 7.4), and the mean particle size and polydispersity index were determined. All measurements were carried out at 251C in the same ionic concentration at a light scattering angle of 901. Zeta potential was determined using an electric field of 150 mV to measure electrophorectic velocity.
Nanoencapsulation efficiency
We used the simple UV-visible spectrophotometry method for estimation of DOX in developed nanovectors [27] . Briefly, 5 mg of DOX was dissolved in 50 ml of distilled water to prepare the stock solution, of which different volumes were used to prepare the working solution. DOX shows maximum absorption at 502 nm scanned using a UV-1700, Pharma Spec Spectrophotometer (Shimadzu). The value of absorbance at 502 nm (A 502 ) of standard DOX solutions was used to produce a plot of A 502 vis-à-vis DOX concentrations, allowing the following standard regression equation in the range of C equal to 10-80 mg/ml to be written as
The drug content was calculated by digesting 10 mg of nanovectors in 5 ml of distilled water. The suspension was warmed for a few minutes and then kept undisturbed for 72 h. It was finally centrifuged at 25 000 rpm, filtered with a 0.2 mm membrane filter (MDI, Ambala, India), and diluted appropriately with a solvent system. The drug content in the system was determined by a spectrophotometric assay at 502 nm (Shimadzu). The experiment was performed in triplicate.
Transmission electron microscopy
The surface morphology of nanovectors was determined using a transmission electron microscope (Philips Morgagni 268; FEI Electron Optics, Eindhoven, the Netherlands) at a constant voltage of 80 kV. A drop of aqueous dispersion of the nanovectors was placed on a carbon-coated copper grid. Subsequently, the grid was allowed to dry in air for 10 min and loaded onto the microscope. A scale bar of 200 nm was used to capture the photomicrographs.
Fourier transform infrared spectroscopy
We used Fourier transform infrared (FTIR) spectroscopy to analyze the chemical compatibility between the drug and the polymer. The spectrum was recorded for DOX, GN, a physical mixture of DOX and GN, and GN-DOX using a Spectrum BX (Perkin Elmer, Waltham, Massachusetts, USA) infrared spectrophotometer. Pellets of samples were prepared with KBr (2 mg sample in 200 mg KBr) using a hydrostatic press at a force of 40 psi for 4 min. The scanning range was 4000-400 cm -1 and the resolution was 4 cm -1 .
Powder X-ray diffraction pattern
To define the crystal structure of the drug in the nanomatrix system, powder X-ray diffraction (PXRD) patterns of DOX, GN, physical mixture of DOX and GN, and GN-DOX were recorded at room temperature using X'Pert PRO, PANalytical diffractometer (PANalytical B.V., Almelo, the Netherlands) with Ni-filtered Cu Ka radiation operated at a voltage of 45 kV, current 40 mA, 1 min -1 scanning speed, and 10-501 diffraction angle (2y) range.
In-vitro drug release profile
The in-vitro drug release of DOX from nanovectors was carried out at 37 ± 11C at slightly acidic pH (5.8) and physiological pH (7.4) in the dark using the dynamic dialysis technique, a method for quantification of drug transport across a dialysis membrane [28] . Briefly, a suspension of GL-GN-DOX and GN-DOX (5 mg dispersed in 1 ml normal saline) was dialyzed against 100 ml of phosphate buffer solution, respectively. At a predetermined time interval, 1 ml of the dissolution medium was withdrawn and replaced with fresh solvent to mimic infinite sink conditions. Absorbance of the withdrawn sample solutions was measured at 502 nm using a UV-visible spectrophotometer (Shimadzu) [27] , and concentration of DOX was calculated using a standard calibration curve.
Therapeutic efficacy of galactosylated and nongalactosylated gelatin nanovectors in vitro and in vivo In-vitro cytotoxicity assay HepG2 (a human hepatocarcinoma cell line) cells were maintained in Roswell Park Memorial Institute 1640 medium containing 10% fetal bovine serum (Biologicals, Israel), 0.1% nonessential amino acids, and 100 U/ml penicillin-streptomycin at 371C with 5% CO 2 . Briefly, 1 Â 10 5 HepG2 cells/well were seeded in 96-well plates and incubated for 24 h to allow the cells to attach. Thereafter, the cells were treated with DOX, GN-DOX and GL-GN-DOX, and GN at a concentration ranging from 0.01 to 1 mg/ml equivalent of DOX. After 72 h of incubation, 50 ml of 3-(4,5-dimethyl-2-thizolyl)-2,5diphenyltertazolium bromide (MTT) solution (5 mg/ml in phosphate-buffered saline) was added to each well, and 3 h later each well was replaced with 100 ml of dimethyl sulfoxide to stop the reaction. Cell viability was quantified by measuring absorbance at 560 nm on a microplate reader (Tecan, Seestrasse, Männedorf, Switzerland).
In-vitro apoptosis assay
We determined the percentage of in-vitro apoptosis using a caspase-3/CPP32 fluorometric assay kit (Biovision, Milpitas, California, USA). HepG2 cells were grown to 70-80% confluence and treated with DOX, GN-DOX, and GL-GN-DOX at a concentration of 0.5 mg/ml equivalent of DOX for 72 h. Cell lysates were prepared by resuspending 1 Â 10 5 cells in 50 ml of chilled lysis buffer and placing it on ice for 10 min. The lysates were incubated with 50 mmol/l of the synthetic substrate DEVD-7-amino-4-trifluoromethyl coumarin at 371C for 2 h. The cleavage of the fluorogenic substrate by caspase-3 was determined in the multidetection microplate reader at 360/528-nm excitation/emission wavelengths.
Pharmacokinetic and biodistribution study
Pharmacokinetic and biodistribution analyses of DOX, GN-DOX, and GL-GN-DOX were carried out using highperformance liquid chromatography (HPLC) for determination of DOX in plasma samples [29] . An in-vivo study was conducted according to the guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals, Ministry of Culture, Government of India, with prior approval from the Institutional Animal Ethics Committee. Swiss albino male mice (20-25 g) were maintained on standard laboratory chow and water ad libitum in the animal house of Hindu College of Pharmacy, Sonepat, India. We randomly divided 81 mice into three groups of 27 animals each, corresponding to the time points of blood collection. Although this gives us three mice per time point for analysis, to prove the statistical significance of the results each sample was analyzed in triplicate and no variation was seen (at 95% confidence level). DOX, GN-DOX, and GL-GN-DOX were administered intravenously (i.v.) through the tail vein at a single dose of 10 mg/kg. Blood samples (500 ml) were collected from the retro-orbital vein by eye puncture into polypropylene microcentrifuge tubes containing 25 ml of 20 mmol/l sodium citrate at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 h for each group. Subsequently, the mice were killed and their visceral organs, such as the heart, liver, kidney, lung, and spleen, were harvested and homogenized separately in 2 ml of normal saline (0.9% w/v NaCl) in a 15 ml centrifuge tube. The blood samples were centrifuged at 4500 rpm for 15 min, and serum was harvested. Subsequently, 200 ml of the collected serum or homogenous mixture of organs was added to 100 ml of acetonitrile (to precipitate the protein). The precipitated proteins were settled by centrifugation at 4500 rpm for 5 min; the supernatant was collected and 100 ml of methanol (HPLC grade) was added. Subsequently, the contents were vortexed (Biohelix, Karnataka, India) for 1 min and again centrifuged at 3000 rpm for 10 min. The supernatant was again filtered through a 0.2 mm membrane filter (MDI) and used for HPLC analysis.
High-performance liquid chromatography analysis
The HPLC system consisted of Agilent Instruments equipped with an Agilent Quaternary pump and a variable wavelength UV detector (Agilent Technologies, Santa Clara, California, USA). The analytical column used was a C18 reversed-phase column (4.6 Â 150 mm) packed with 5 mm particles. The mobile phase consisted of water : acetonitrile (75 : 25). The solvent system was filtered and degassed by vacuum filtration through a 0.2 mm membrane filter (MDI) before use. The flow rate of the mobile phase was adjusted to 1 ml/min, and the column temperature was set at 251C. The wavelength of detection was 254 nm set at 0.005 absorbance unit full scale.
Pharmacokinetic analysis using the one-compartment model
Plasma concentration data were analyzed using the onecompartment model, and the following pharmacokinetic parameters were assessed: elimination rate constant (k e ; h -1 ), disposition half-life (t 1/2 ; h), area under the curve (AUC; mg h/ml), area under the curve from zero to infinity (AUC inf ; mg h/ml), area under the first moment curve (AUMC; mg h 2 /ml), area under the first moment curve from zero to infinity (AUMC inf ; mg h 2 /ml), mean residence time (MRT; h), total body clearance (CL total ; l/h), and volume of distribution (V d ; l).
k e was calculated from the slope of the data points in the final semilogarithmic drug-concentration time plot by weighted least square linear regression analysis. The t 1/2 value was calculated using the following equation:
AUC 0-t was calculated using the linear trapezoidal method, and AUC inf was calculated using the following equation:
where AUC last represents the area under the curve up to the last sampling point with detectable levels and k e represents the elimination rate constant.
AUMC is obtained from a plot of the product of plasma drug concentration and time (C Â t) versus time t from zero to infinity. MRT can be calculated using the following equation:
ð4Þ Similarly, CL total can be calculated from dose/AUC inf and V d , which represents volume of distribution obtained from CL total /k e .
Statistical analysis
Statistical analysis was carried out using one-way and twoway analysis of variance (ANOVA). All results were expressed as mean ± SD for n of at least 3. A probability (P) value of less than 0.05 was considered statistically significant.
Results and Discussion

Characterization of galactose conjugation over the surface of gelatin nanovectors
We have synthesized and characterized galactosylated gelatin nanovectors by conjugating lactobionic acid with gelatin, followed by encapsulation of DOX in galactosylated nanovectors. The conjugation of lactobionic acid with gelatin requires activation of its carbonyl group. This allows the active targeting of nanovectors on cells through a receptor-mediated endocytosis pathway. The galactose moiety was conjugated to GNs using the activated carbonyl group of lactobionic acid, and the conjugation was confirmed by DSC. GN exhibits an endothermic peak at 116.041C. However, galactosylated nanovectors show a sharp endothermic peak at 174.321C in comparison with 114.7841C shown by lactobionic acid (Table 1) .
This confirms that after conjugation with lactobionic acid the rigidity of GN increases, which further shifts the endothermic peak of conjugated nanovectors to a higher temperature. These results are consistent with a study published previously [30] . This reaction was also confirmed by determining the free amine groups in modified and unmodified formulation using TNBS assay, in which 45% of the amine groups in gelatin were found to be modified with lactobionic acid.
Synthesis and characterization of galactosylated gelatin nanovectors
GNs were successfully prepared by the nanoemulsion method using the highly monodispersed aqueous core of AOT/n-hexane reverse micellar droplets [15, 26] . The size of the inner aqueous core of reverse micelles was in the nanometer range; hence, the GNs prepared inside these reverse micelles had an average size of 85.2 ± 10.4 nm (polydispersity index 0.09 ± 0.01) with a zeta potential of -40.3 ± 0.9 mV ( Table 2 ). The mean particle size of GN-DOX was found to be 88.3 ± 9.3 nm (polydispersity index 0.08 ± 0.02) with zeta potential of -41 ± 0.1 mV and encapsulation efficiency of 50.4 ± 3.2%. However, the surface modification further enhanced the particle size of GNs and showed a mean diameter of 95.1 ± 11.6 nm in GL-GN-DOX with encapsulation efficiency of 53.6 ± 1.2% and zeta potential of -45.4 ± 0.2 mV. The decrease in zeta potential of GL-GN-DOX in comparison with GN-DOX also assured the presence of galactose over the surface of nanovectors. Transmission electron micrographs of GN-DOX and GL-GN-DOX revealed the spherical shape of the GNs (Fig. 2) . Further, the photomicrographs established their nanometric size, which also augmented upon galactosylation. As most of the peripheral human tumor vessels have a permeability cutoff of less than 600 nm, GN-DOX and GL-GN-DOX may therefore be used efficiently for drug delivery to liver tumor after intravenous or intratumoral administration [31] . FTIR spectra were recorded to analyze the structure of any new chemical linkage formed during the encapsulation of DOX in the nanoparticle matrix. The FTIR spectrum peaks of DOX, GN, physical mixture of DOX and GN, and GN-DOX are shown in Table 3 . The assignment of FTIR scan indicates that DOX exhibits its characteristic peak at 2935 cm -1 , indicating the presence of an intact -OCH 3 group. Other observed peaks of DOX are 3284 cm -1 for N-H stretching, 1617 cm -1 for C = O stretching, 1462 cm -1 for C = C stretching, 1377 cm -1 for O-H bending, 1331 cm -1 for C-N stretching, 1085 cm -1 for C-O stretching, and 1023 cm -1 for C-O-C bending. The spectrum of GN reveals a characteristic vibration at 3411 cm -1 , indicating the presence of N-H stretching in secondary amide. Other vibrations observed are 1625 cm -1 (C = O stretching in protein backbone), 1109 cm -1 (C-N stretching), and 637 cm -1 (N-H bending). These peaks were almost unchanged in GN-DOX along with the characteristic peak of DOX at 2949 cm -1 (-OCH 3 stretching), which indicates stability and the presence of DOX in GNs. These studies corroborate that there is no significant interaction between DOX and GNs. Further, PXRD patterns were recorded to define the crystal structure of the drug after loading in the GNs. The PXRD pattern of DOX shows a sharp and intense peak indicating its crystalline structure, whereas GNs showed only a few sharp peaks and most diffused peaks ( Fig. 3a-d) . The physical mixture of DOX and GNs showed a few sharp peaks, indicating the presence of DOX. The rest of the peaks were broad and diffused with low intensity, signifying the amorphous nature of GNs. Finally, the PXRD pattern of GN-DOX revealed sharp peaks of diminished intensities. This suggested that DOX is present in a wettable amorphous state in the nanomatrix system, which is more bioavailable than free DOX solution. The amorphous state due to the absence of an ordered crystal lattice requires minimal energy and thus provides the maximal solubility and bioavailability of drugs. However, limitations of amorphous systems such as physical instability and higher chemical reactivity act as a hurdle in their extensive commercialization. Therefore, polymers are usually used to provide an amorphous matrix in which the drug can dissolve, whereby the viscosity of the matrix is usually high enough to prevent recrystallization on storage. We recovered the GNs as a fine dry powder in the form of a molecular dispersion, providing close contact between the components, thus generating a stable form even under accelerated stability conditions.
In-vitro release profile
The drug release kinetic from polymeric nanoparticles depends on the rate of water uptake, drug dissolution/ diffusion rate, and polymer glass-rubbery transition including the matrix erosion or degradation rate. We observed that release of DOX from two formulations (GL-GN-DOX and GN-DOX) follows a pH-dependent release. The GL-GN-DOX and GN-DOX formulations release 65.9 ± 5.4 and 54.9 ± 4.3% of DOX at pH 5.8, whereas 28.8 ± 4.3 and 24.7 ± 3.4% of DOX were released, respectively, at pH 7.4 initially at 8 h (Fig. 4) .
However, at 24 h, GN-DOX releases 86.6 ± 6.5% of DOX, whereas GL-GN-DOX releases 95.2 ± 4.3% of DOX at pH 5.8. This release was significantly (P < 0.05) higher than DOX released (GN-DOX, 50.6 ± 3.2%; GL-GN-DOX, 55.8 ± 3.4%) at pH 7.4. For systemic delivery of cytotoxic agents to the tumor vasculature, the drug candidate must be able to move through the circulatory system and overcome the P-glycoprotein resistance. However, because of irregular blood supply, high interstitial pressure, and slightly acidic pH (due to deposition of lactic acid) there is inefficient drug uptake and disposition in tumor tissues. We investigated the release of higher amounts of DOX by GL-GN-DOX and GN-DOX in slightly acidic pH (5.8) and suppression of the release rate at pH 7.4. This may be attributed to the rigidity of GN at physiological pH, which prevents the swelling of crosslinked gelatin and thus reduces the release rate. However, slightly acidic pH increases the GN size/degree of swelling or rate of water uptake, which further enhances the release rate [18] .
Analysis of in-vitro cytotoxicity and apoptosis in HepG2 cells
Consistent with the study published previously [24] , we found that all three formulations, that is, DOX, GN-DOX, and GL-GN-DOX, showed clear dose-dependent cytotoxicity in HepG2 cells at a concentration ranging from 0.01 to 1 mg/ml equivalent of DOX. However, blank GN did not show any toxicity in HepG2 cells (data not shown). After interpretation of the in-vitro cytotoxicity data, we observed that the inhibitory concentration (IC 50 ) value of GL-GN-DOX (0.35 mg/ml) significantly decreased in comparison with that of GN-DOX (0.75 mg/ml) and free DOX (0.91 mg/ml) solution (Fig. 5a) . The low IC 50 value and enhanced cytotoxicity of GL-GN-DOX formulation may be attributed to the selective uptake of the galactosylated nanovectors by HepG2 cells. Further, we selected 0.5 mg/ml equivalent of DOX in all three formulations to study in-vitro cellular apoptosis.
To investigate the influence of galactosylated nanovectors in induction of apoptosis in HepG2 cells, we used the caspase-3 apoptosis assay kit to measure the apoptosis in treated cells. Caspase-3 plays a vital role in the terminal execution phase of apoptosis induced by diverse stimuli. GL-GN-DOX induced a marked increase of DEVDspecific caspase-3 activity with the degradation of procaspase-3 in treated HepG2 cells and exhibited 67.8% of apoptosis in comparison with 43.5% induced by GN-DOX and 25.3% induced by free DOX solution (Fig. 5b) . Hence, the data from MTT assay and in-vitro cellular apoptosis indicate that GL-GN-DOX may be used as an eligible candidate for further in-vivo study.
Pharmacokinetic and biodistribution analysis
We have administered a single i.v. injection at an equivalent dose of 10 mg/kg in male mice and processed the pharmacokinetic data of DOX, GN-DOX, and Table 4 . The pharmacokinetic data clearly revealed that biodis-tribution of DOX was significantly altered when delivered through nanovector formulations. Comparing the phar-macokinetic profile of three formulations, that is, DOX, GN-DOX, and GL-GN-DOX, we observed the higher plasma concentration and longer retention time of DOX after i.v. injection of GL-GN-DOX in mice. The free DOX solution exhibited a rapid clearance from the blood with an elimination rate constant of 0.394 ± 0.02 h -1 . However, in the case of GN-DOX and GL-GN-DOX, the .55 ± 5.28) further demonstrated the prolonged circulation potential of nanovectors and were a maximum for GL-GN-DOX (P < 0.05; one-way ANOVA test). In addition, the plasma half-life (t 1/2 ) of DOX loaded in GN-DOX and GL-GN-DOX in comparison with free DOX was increased by 2.5-and 5.9-fold, respectively, indicating the maximum residence time of drug loaded in GL-GN-DOX in the systemic circulation. These results indicated that galactosylation lowered the rate of drug diffusion and caused prolonged release of DOX from nanovectors. The biodistribution profiles of all three formulations were also investigated to establish the efficacy of galactosylated nanovectors. The distribution of free DOX, GN-DOX, and GL-GN-DOX in different tissues (target as well as nontarget) was determined at different time points (Table 4 ). At all time points, the concentration of DOX in liver samples was higher for GL-GN-DOX than for GN-DOX and free DOX solution. For example, peak liver concentration of GL-GN-DOX was 24.5 mg/g at 1 h, whereas the peak concentrations of GN-DOX and DOX were relatively low (16.2 and 9.8 mg/g; P < 0.05; one-way ANOVA test) at 1 h. The concentration of free DOX was found to be highest in the kidney, in which 8.8 mg/g of drug was localized after 2 h. This may be attributed to the fact that kidney is the principal excretory organ for drug clearance. Further, in heart samples 3.2 mg/g of free DOX was detectable 24 h after administration. In contrast, after 24 h of administration, the concentrations of DOX deposited by GN-DOX and GL-GN-DOX were measured as 0.6 and 0.3 mg/g, respectively. As GL-GN-DOX significantly diminished the delivery of DOX to the heart, this indicates its prospective ability to reduce the cardiotoxicity associated with conventional DOX therapy.
Conclusion
The present study reveals the prospective ability of galactosylated nanovectors as efficient carriers to ferry large doses of DOX. The galactosylated nanovectors engineered from the nanoemulsion method could effectively incorporate DOX and exhibited a spherical shape with a smooth surface and had an average size of less than 100 nm. Further, we showed that release of DOX from the gelatin nanomatrix system follows a pH-responsive release profile. The galactosylated nanovectors were selectively taken up by HepG2 cells and exhibited enhanced cytotoxicity and apoptosis compared with the unmodified formulation. Moreover, the result of the tissue distribution study proves that the recognition of galactosylated residues by ASGP receptor on the surface of parenchymal cells induces the liver accumulation of GL-GN-DOX. Thus, galactosylated gelatin nanovectors of doxorubicin warrant future in-depth in-vivo antitumor study to scale-up the technology and may be used as a chemotherapeutic agent in the management of hepatocarcinoma.
